Beau's lines
Methodology & AI Transparency ⓘ
Beau's lines Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as L60.4, Beau's lines falls under Hair & Scalp management, where early follicle preservation in Beau's lines (L60.4: with 5-alpha-reductase modulators) establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Beau's lines uses ICD-10 L60.4 across Hair & Scalp specialty care.
- 3 Typical cash cost range: Differential triage of Beau's lines (L60.4) utilizes early follicle preservation in Beau's lines (L60.4: with 5-alpha-reductase modulators).
- 4 Top reported side effects / signs: Objective lab/clinical target for Beau's lines: Total/Free Testosterone & in Beau's lines (L60.4: DHEA-S (if androgenic)) (Age/sex physiological range (L60.4)) and Serum Ferritin [Beau's lines L60.4].
Ask our AI Specialists anything about Beau's lines
What Is Beau's lines?
Designated in federal medical registries as L60.4, Beau's lines falls under Hair & Scalp management, where early follicle preservation in Beau's lines (L60.4: with 5-alpha-reductase modulators) establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Beau's lines (ICD-10 L60.4) is driven by perifollicular autoimmune lymphocytic in Beau's lines (L60.4: attack (alopecia areata)); specialists in Hair Loss, Alopecia & Scalp Conditions monitor Serum Ferritin [Beau's lines L60.4] to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Beau's lines (L60.4): thickened, discolored, brittle, in Beau's lines (L60.4: or subungually lifting)
- • Secondary Beau's lines clinical sign: gradual widening of in Beau's lines (L60.4: the central scalp)
- • Symptom flares in Beau's lines correlating with Total/Free Testosterone & in Beau's lines (L60.4: DHEA-S (if androgenic)) deviation outside Age/sex physiological range (L60.4)
- • Functional hair & scalp impact requiring early follicle preservation in Beau's lines (L60.4: with 5-alpha-reductase modulators) evaluation (L60.4)
Beau's lines Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L60.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Hair Loss, Alopecia & Scalp Conditions | NLM Clinical Tables |
| Diagnostic / Lab Marker: Total/Free Testosterone & in Beau's lines (L60.4: DHEA-S (if androgenic)) | Age/sex physiological range (L60.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin [Beau's lines L60.4] | 70 – 150 ng/mL (L60.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Free in Beau's lines (L60.4: T4) | TSH 0.8 – 2.5 mIU/L (L60.4) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Beau's lines
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Tissen NF 10 (Adenosine) Tissen NF 10 • RxCUI RXN-B424911100 | Adenosine Receptor Agonist | 85% | $2.1000 | $ 159.70 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Beau's lines)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on A randomized, compared against a dummy pill (placebo) trial of 5% and 2%: What a 381-Participant Study Found In this 48-week study of 381 women with female pattern hair loss, 5% applied to the skin minoxidil was superior to placebo on each of the 3 primary efficacy end points: promoting hair growth as measured by change in nonvellus... Journal of the American Academy of Dermatology • 2004-04-15 • Randomized Controlled Trial | N = 381 | 93/100 | PMID 15034503 ↗ |
| What the Latest Evidence Really Says About Treatments for hair loss areata: a network We also found that the impact of other treatments on hair regrowth is very uncertain. The Cochrane database of systematic reviews • 2023-10-23 • Meta-Analysis | N = 25 | 92/100 | PMID 37870096 ↗ |
| What the Latest Evidence Really Says About Effectiveness of treatments for androgenetic hair This meta-analysis strongly suggests that minoxidil, finasteride, and low-level laser light therapy are effective for promoting hair growth in men with androgenetic hair loss and that minoxidil is effective in women with... Journal of the American Academy of Dermatology • 2017-07-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 28396101 ↗ |
| What the Latest Evidence Really Says About Efficacy of non-surgical treatments for androgenetic hair High-quality randomized controlled trials and head-to-head trials are required to support these findings and aid in the development of more standardized protocols, particularly for PRP. Journal of the European Academy of Dermatology and Venereology : JEADV • 2018-12-15 • Meta-Analysis | N = 45 | 92/100 | PMID 29797431 ↗ |
| Can This Approach Help? Inside the Latest Research on Platelet-rich Plasma for Androgenetic hair loss Treatment: A Randomized compared No improvements were seen over the course of the trial, using TrichoScan measurements or visual assessment. Acta dermato-venereologica • 2020-08-18 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 32735021 ↗ |
Beau's lines Patient Community & “People Like Me” Threads
Filter Beau's lines community threads and patient logs by age, biological sex, dosage, and treatment duration.